Boston Trust Walden Corp Buys 37,835 Shares of Amdocs Limited $DOX

Boston Trust Walden Corp increased its stake in Amdocs Limited (NASDAQ:DOX) by 5.9% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 678,929 shares of the technology company’s stock after acquiring an additional 37,835 shares during the quarter. Boston Trust Walden Corp owned 0.60% of Amdocs worth $61,945,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Pzena Investment Management LLC increased its stake in shares of Amdocs by 2.1% in the 2nd quarter. Pzena Investment Management LLC now owns 6,551,065 shares of the technology company’s stock valued at $597,719,000 after acquiring an additional 132,463 shares in the last quarter. LSV Asset Management increased its stake in shares of Amdocs by 11.1% in the 1st quarter. LSV Asset Management now owns 3,180,501 shares of the technology company’s stock valued at $291,016,000 after acquiring an additional 317,412 shares in the last quarter. Alyeska Investment Group L.P. increased its stake in shares of Amdocs by 38.6% in the 1st quarter. Alyeska Investment Group L.P. now owns 2,329,767 shares of the technology company’s stock valued at $213,174,000 after acquiring an additional 648,693 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Amdocs by 23.5% in the 1st quarter. American Century Companies Inc. now owns 2,242,829 shares of the technology company’s stock valued at $205,219,000 after acquiring an additional 426,911 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Amdocs by 9.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,120,075 shares of the technology company’s stock valued at $193,978,000 after acquiring an additional 182,489 shares in the last quarter. Institutional investors own 92.02% of the company’s stock.

Amdocs Stock Performance

Shares of DOX stock opened at $81.44 on Tuesday. The firm has a market capitalization of $9.19 billion, a PE ratio of 16.52, a price-to-earnings-growth ratio of 1.34 and a beta of 0.51. The firm has a fifty day simple moving average of $84.73 and a two-hundred day simple moving average of $87.61. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 0.23. Amdocs Limited has a 12 month low of $78.61 and a 12 month high of $95.41.

Amdocs (NASDAQ:DOX) last posted its earnings results on Wednesday, August 6th. The technology company reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.71 by $0.01. Amdocs had a net margin of 11.94% and a return on equity of 19.66%. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the business posted $1.62 EPS. The business’s revenue was down 8.4% compared to the same quarter last year. Analysts forecast that Amdocs Limited will post 6.21 EPS for the current fiscal year.

Amdocs Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.527 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $2.11 annualized dividend and a dividend yield of 2.6%. Amdocs’s dividend payout ratio is presently 42.80%.

Analyst Upgrades and Downgrades

DOX has been the subject of several research analyst reports. Wall Street Zen upgraded shares of Amdocs from a “hold” rating to a “buy” rating in a research note on Saturday. Weiss Ratings restated a “hold (c+)” rating on shares of Amdocs in a research note on Wednesday, October 8th. Finally, Wolfe Research assumed coverage on shares of Amdocs in a research note on Tuesday, July 8th. They set an “outperform” rating for the company. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Amdocs has an average rating of “Moderate Buy” and an average price target of $108.00.

Amdocs Company Profile

Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.